

Dispersome® Make your drug soluble

Dispersome® is a solubility enhancement technology that relies on an innovative and naturally occurring excipient to develop amorphous solid dispersions with high drug loading and high bioavailability.



Beta-lactoglobulin as pharmaceutical excipient

Proteins comprise a new group of excipients for preparing amorphous solid dispersions. Beta-lactoglobulin (BLG), the main component in Dispersome formulations, results in superior drug solubility compared to other proteins. Hovione has developed a partnership with Zerion Pharma who has a strong IP portfolio covering protein-based excipients for solid dispersions with patent life beyond 2040.

Stable formulations with high drug loading

The use of Dispersome® technology enables drug loadings above 50% w/w while maintaining stability and improving API solubility. At a drug loading of 50%, stable amorphous formulations are obtained for more than 80% of all drugs tested.

Superior outcomes, compatible technology

By increasing drug solubility, the Dispersome® platform aims at improving oral bioavailability and therapeutic outcomes for patients. Dispersome® formulations are compatible with standard pharmaceutical processes and Spray Drying provides a scalable manufacturing solution.

Dispersome® is now part of ASD-HIPROS the most advanced and accurate screening tool to identify the best Amorphous Solid Dispersion formulations by Spray Drying.


A safe and manufacturable excipient

We work with world leading suppliers to source and qualify our BLG material, ensuring high quality and large scale supply. BLG is a natural ingredient used in food and nutrition products and is easy to integrate in your existing processes.


Contact us today to solve your solubility challenges:
dispersome@hovione.com | www.hovione.com

The Trademark Dispersome® is used under license from Zerion

Dispersome® formulation achieves a superior dissolution rate and better solubility compared to other solid dispersions when addressing a poorly soluble drug like ZN-X.



Dispersome® formulations result in a substantial solubility increase for most poorly soluble drugs, compared to the crystalline form of the drug.



Your preferred solubility partner

We invite you to test the performance of your formulation using Dispersome® Technology. Our partner Zerion has successfully used this technology on multiple drug molecules from pharma companies.